Applied Molecular Transport to Present at SVB Leerink 10th Annual Global Healthcare Conference

Rhea-AI Summary

Applied Molecular Transport Inc. (Nasdaq: AMTI) announced that CEO Tahir Mahmood will participate in a fireside chat at the SVB Leerink 10th Annual Global Healthcare Conference on February 25, 2021, at 4:20 p.m. ET. A live webcast will be available on the company's website, with an archived replay accessible for 30 days post-event.

AMTI is a clinical-stage biopharmaceutical firm focused on developing novel oral biologics for autoimmune and inflammatory diseases using a proprietary technology platform.

SOUTH SAN FRANCISCO, Calif., Feb. 17, 2021 (GLOBE NEWSWIRE) -- Applied Molecular Transport Inc. (Nasdaq: AMTI) (AMT), a clinical-stage biopharmaceutical company, today announced that Tahir Mahmood, Ph.D., chief executive officer and co-founder, will participate in a fireside chat during the SVB Leerink 10^th Annual Global Healthcare Conference on Thursday, February 25, 2021 at 4:20 p.m. ET.

A live webcast will be accessible via the Events page of the Applied Molecular Transport website at https://ir.appliedmt.com/news-events/events. An archived replay will be available for 30 days following the event.

About Applied Molecular Transport Inc.
Applied Molecular Transport Inc. is a clinical-stage biopharmaceutical company leveraging its proprietary technology platform to design and develop a pipeline of novel oral biologic product candidates to treat autoimmune, inflammatory, metabolic, and other diseases. AMT’s proprietary technology platform allows it to exploit existing natural cellular trafficking pathways to facilitate the active transport of diverse therapeutic modalities across the intestinal epithelium (IE) barrier. Active transport is an efficient mechanism that uses the cell’s own machinery to transport materials across the IE barrier. AMT believes that its ability to exploit this mechanism is a key differentiator of its approach. AMT is developing additional oral biologic product candidates in patient-friendly oral forms that are designed to either target local gastrointestinal tissue or enter systemic circulation to precisely address the relevant biology of a disease.

AMT’s headquarters, internal GMP manufacturing and lab facilities are located in South San Francisco, CA. For additional information on AMT, please visit www.appliedmt.com.

Investor Relations Contact:
Andrew Chang
Head, Investor Relations & Corporate Communications
achang@appliedmt.com

Media Contacts:
Alexandra Santos
Wheelhouse Life Science Advisors
asantos@wheelhouselsa.com

Aljanae Reynolds
Wheelhouse Life Science Advisors
areynolds@wheelhouselsa.com 

FAQ

When will AMTI's CEO participate in the SVB Leerink Global Healthcare Conference?

CEO Tahir Mahmood will participate in the conference on February 25, 2021, at 4:20 p.m. ET.

How can I access the live webcast of AMTI's event?

The live webcast can be accessed via the Events page on the Applied Molecular Transport website.

What is the focus of Applied Molecular Transport Inc.?

AMTI focuses on developing novel oral biologics to treat autoimmune, inflammatory, and metabolic diseases.

Is there a replay available for AMTI's conference presentation?

Yes, an archived replay will be available for 30 days following the event.

What technology does AMTI utilize in its product development?

AMTI leverages a proprietary technology platform for the active transport of therapeutic modalities across the intestinal epithelium.